Testing the Use of Ado-Trastuzumab Emtansine Compared to the Usual Treatment (Chemotherapy With Docetaxel Plus Trastuzumab) or Trastuzumab Deruxtecan for Recurrent, Metastatic, or Unresectable HER2-Expressing Salivary Gland Cancers
for Metastatic Salivary Gland Carcinoma
150 locations incl. Birmingham
Sponsor: NRG Oncology
Sex: All·Age: 18+
Code: NCT05408845·Phase 2·Recruiting